Rosemont to Acquire Aytu BioPharma in All-Cash Tender Offer
Story updates
09:06:46 PM UTC
SquawkNews
Agreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per shareTender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% premium to the closing price on November 13, 2026Tender offer support agreements secured from Nantahala Capital…
09:06:55 PM UTC
SquawkNews
AYTU BIOPHARMA - TENDER OFFER TO BUY ALL SHARES FOR $2.7 PER SHARE IN CASH - SEC FILING
09:11:32 PM UTC
SquawkNews
Rosemont Pharmaceuticals agrees to acquire Aytu BioPharma for $2.70 per share Rosemont Pharmaceu
09:11:42 PM UTC
SquawkNews
Agreement to acquire Aytu BioPharma for all-cash consideration of $2.70 per Aytu share. Proposed acq